Evidence map›Paper›PMID 31866798›Full record

ArticleContrast media & molecular imaging2019

Imaging Fibrogenesis in a Diet-Induced Model of Nonalcoholic Steatohepatitis (NASH).

S V Hartimath, R Boominathan, V Soh, P Cheng, X Deng, Y C Chong, F F Yong, P W Tan, W Han, E G Robins and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Contrast media & molecular imaging, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025
    Article
  2. Review
  3. Article
  4. Article
  5. Targeting integrin pathways: mechanisms and advances in therapy.Signal transduction and targeted therapy · 2023
    Review
  6. MERTKInternational journal of molecular sciences · 2021
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

S V HartimathSingapore Bioimaging Consortium, Agency for Science Technology and Research (A∗STAR), 11 Biopolis Way, #01-02 Helios, Singapore 138667, Singapore.
R BoominathanSingapore Bioimaging Consortium, Agency for Science Technology and Research (A∗STAR), 11 Biopolis Way, #01-02 Helios, Singapore 138667, Singapore.
V SohSingapore Bioimaging Consortium, Agency for Science Technology and Research (A∗STAR), 11 Biopolis Way, #01-02 Helios, Singapore 138667, Singapore.
P ChengSingapore Bioimaging Consortium, Agency for Science Technology and Research (A∗STAR), 11 Biopolis Way, #01-02 Helios, Singapore 138667, Singapore.
X DengSingapore Bioimaging Consortium, Agency for Science Technology and Research (A∗STAR), 11 Biopolis Way, #01-02 Helios, Singapore 138667, Singapore.
Y C ChongSingapore Bioimaging Consortium, Agency for Science Technology and Research (A∗STAR), 11 Biopolis Way, #01-02 Helios, Singapore 138667, Singapore.
F F YongSingapore Bioimaging Consortium, Agency for Science Technology and Research (A∗STAR), 11 Biopolis Way, #01-02 Helios, Singapore 138667, Singapore.
P W TanSingapore Bioimaging Consortium, Agency for Science Technology and Research (A∗STAR), 11 Biopolis Way, #01-02 Helios, Singapore 138667, Singapore.
W HanSingapore Bioimaging Consortium, Agency for Science Technology and Research (A∗STAR), 11 Biopolis Way, #01-02 Helios, Singapore 138667, Singapore.
E G RobinsSingapore Bioimaging Consortium, Agency for Science Technology and Research (A∗STAR), 11 Biopolis Way, #01-02 Helios, Singapore 138667, Singapore.
J L GoggiSingapore Bioimaging Consortium, Agency for Science Technology and Research (A∗STAR), 11 Biopolis Way, #01-02 Helios, Singapore 138667, Singapore.ORCID 0000-0002-3021-3184
Agency for Science, Technology and Research · SG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Liver fibrosis is the hallmark of chronic nonalcoholic steatohepatitis (NASH) and is characterised by the excessive deposition of extracellular matrix proteins. Early detection and accurate staging of liver fibrosis is critically important for patient management. One of the earliest pathological markers in NASH is the activation of hepatic stellate cells (HSCs) which may be exploited as a marker of fibrogenesis. Activated HSCs secreting factors such as integrin Procedures: Mice were fed with either standard chow diet (SD), high-fat diet (HFD), or a choline-deficient, L-amino acid-defined high-fat fibrogenic diet (CDAHFD) to mimic the clinical pathology of liver disease and followed longitudinally for 10 weeks to assess the development of liver fibrosis using [ Results: The CDAHFD fibrogenic diet predictably developed hepatic inflammation and steatosis over the 10 weeks studied with little NASH pathology detected in high fat diet-treated animals. Stage 1 fibrosis was detected early by histology at day 21 and progressed to stage 2 by day 35 and stage 3 by day 56 in mice fed with CDAHFD diet only. Noninvasive imaging with [ Conclusions: The diet-induced progression of liver fibrosis was confirmed using histology and correlated well with the mRNA of integrin

Indexed as

Positron-Emission TomographyActinsAnimalsCholine DeficiencyCollagenDiet, High-FatDisease ProgressionEarly DiagnosisFluorine RadioisotopesGene Expression RegulationHepatic Stellate CellsHydroxyprolineIntegrin alphaVbeta3LiverLiver CirrhosisMaleActinsCollagenFluorine-18Fluorine RadioisotopesHydroxyprolineIntegrin alphaVbeta3RadiopharmaceuticalsRNA, MessengerTriglycerides

Identifiers

PMID31866798
PMCPMC6914933
OpenAlexW2992508842

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.